Deal Watch: Immuno-Oncology Double-Header At Bristol With Rigel, Flexus Deals
Executive Summary
Valeant jumps back into M&A, acquiring Salix after wholesale inventory issues discouraged other potential buyers. Merck more or less options a pipeline with its five-year R&D collaboration with NGM Pharma.